

CURRICULUM VITAE

JOHN M. MAGGIANO, B.S., M.D.
Fellow, American Academy of Ophthalmology
Qualified Medical Examiner, State of California

Mailing/Contact Address:
Orange County Retina Medical Group
1200 North Tustin Avenue, Suite 140
Santa Ana, California 92705
714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Founding Partner
1/1/1979 – Present

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

EDUCATION AND TRAINING

Vitreo-Retinal Fellowship

The Eye Institute of The Medical College of Wisconsin, Milwaukee, Wisconsin, 1977-1978
Thomas M. Aaberg, MD, Director, Retinal Section / Richard Schultz, MD, Chief

Medical Retina and Retinal Physiology Fellowship

Post-Doctoral Fellowship in Medical and Hereditary Retinal Diseases
National Institutes of Health, PHS Grant #EY 24-19
Gerald A. Fishman, MD, Preceptor / Morton F. Goldberg, MD, Chief
Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, 1976-1977

Residency in Ophthalmology

Loyola University Affiliated Hospital, Chicago, Illinois
James E. McDonald, MD, Chief, 1973-1976

Medical Education

Medical Doctorate
Loyola University, Stritch School of Medicine, Chicago, Illinois, 1969-1973

Honors Program, Computers in Clinical Medicine
Division of Computer Research and Technology, William Mohler, MD
National Institutes of Health, Bethesda, Maryland, January -March, 1973

Undergraduate Education

B.S. Degree in Biological Sciences (Minor in Computer Science, Biostatistics)
University of California, Irvine, Irvine, California, 1965 – 1969

Honors Program Statistics in the Health Sciences-Eleventh Summer
Program National Institutes of Health, University of Washington, Seattle, 1969

Secondary Education

Santa Ana Valley High School, Santa Ana, California, 1962 – 1965

Exchange Student, American Field Service, Neues Gymnasium, Göttingen, Germany, 1964 - 1965

BOARD CERTIFICATION

National Board of Medical Examiners, 1974

American Board of Ophthalmology, 1977

LICENSURE

California, Issued 1976

ACADEMIC APPOINTMENTS/PROFESSIONAL POSITIONS

Attending Physician, Ophthalmology Section

Hines Veterans Administration Hospital, Hines, Illinois, 1976-1977

Clinical Instructor, Ophthalmology

Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, 1976-1977

Clinical Instructor, Ophthalmology

Loyola University Medical Center, Chicago, Illinois, 1976-1977

Assistant Professor, Ophthalmology, University of California, Irvine

Irvine, California, 1978-1979

Attending Physician, Ophthalmology

Long Beach Veterans Administration Hospital, Long Beach, California, 1979-1998

Associate Clinical Professor, Ophthalmology

University of California, Irvine, Irvine, California, 1992-Present

Teaching Faculty, Alcon Surgical, 1990-Present

PROFESSIONAL SOCIETY MEMBERSHIPS

1977-Present	The Macula Society, Founding Member
1979-Present	American Academy of Ophthalmology, Fellow
1973-Present	Association for Research in Vision and Ophthalmology
1973-1994	American Medical Association
1976-1990	International Society for Clinical Electrophysiology in Vision
1979-Present	California Medical Association
1979-Present	Orange County Medical Association
1978-Present	California Academy of Eye Physicians and Surgeons
1978-Present	Orange County Society of Ophthalmology Member, 1978 Assistant Program Chairman, 1980 Program Chairman, 1981 Secretary, 1982 Treasurer, 1983 Vice President, 1984 President, 1985
1989-Present	American Diabetes Association California Affiliate, Orange County Chapter Board Member, 1989-1991 Patient Education Committee, 1989-1996 American Association of Diabetes Educators, 1994-2004
1994-Present	American Society of Retina Specialists (The Vitreous Society)

HOSPITAL STAFF AFFILIATIONS

1978-Present	Medical Center, University of California at Irvine, Irvine, California
1978-Present	Western Medical Center, Santa Ana, California
1979-2011	St. Joseph Hospital, Orange, California
1980-Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
1991-2011	Children's Hospital of Orange County, Orange, California

PROFESSIONAL PRESENTATIONS

01. *The Electro-Oculogram in Response to Near UV and Near IR Light*
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1975
02. *Ocular Findings Associated with Iq+ Chromosomes*
Association for Research in Vision & Ophthalmology, Portland, Oregon; September 1975
03. *Eye Injuries*
Northern Illinois Association of Industrial Nurses, Chicago, Illinois; October 1975
04. *The Exacerbation of Behcet's Syndrome by Ingestion of English Walnuts*
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1976
05. *Rod-Cone Dystrophy and Nanophthalmos*
Association for Research in Vision & Ophthalmology, Sarasota, Florida; April 1977
06. *Rod-Cone Dystrophy and Alopecia Areata Universalis*
International Society for Clinical Electoretinography, Ghent, Belgium; June 1977
07. *The Fundus as a Window to Systemic Diseases*
The Medical College of Wisconsin, Department of Internal Medicine, Lecture Series, Milwaukee, Wisconsin; September 1977
08. *Electrophysiologic Changes in Juvenile X-Linked Retinoschisis*
Association for Research in Vision & Ophthalmology, Sarasota, Florida; May 1978
09. *A Study of the Effects of Retroseptal and Oral Corticosteroids on Serous Choroidal Detachment After Retinal Detachment Surgery*
Ocular Drug Therapy Update '78, Newport Beach, California; September 1978
10. *Choroidal Edema, Hemorrhagic and Serous: Clinical and Experimental Correlation*
XIth Meeting of Club Jules Gonin Society, Barcelona, Spain; October 1978
Presentation by Thomas M. Aaberg, MD
11. *Tamoxifen Retinopathy*
The Macula Society, Sonesta Beach, Florida; January 1979
Presentation by Mano Swartz, MD
12. *Factors Influencing Formation of Serous Choroidal Detachment After Retinal Detachment Surgery*
Association for Research in Vision & Ophthalmology, Sarasota, Florida; May 1979
13. *Ocular Electrophysiology*
Western Medical Center, Santa Ana, California; August 1979
14. *A Review of the Diabetic Retinopathy Vitrectomy Study*
Western Medical Center, Santa Ana, California; June 1981
15. *Ultrasonography of the Eye and Orbit*
Hoag Memorial Hospital, Presbyterian, Newport Beach, California; June 1981
16. *Indications for Anterior Segment Vitrectomy*
Phoenix Eye Society, Phoenix, Arizona; October 1981

17. *Pre-Vitrectomy Macular Function Testing*
The Macula Society, Orlando, Florida; January 1983
18. *Opaque Media Testing--Current Concepts in Penetrating Keratoplasty*
Western Medical Center/Orange County Eye Bank, Santa Ana, California; February 1983
19. *Understanding Diabetic Retinopathy*
Diabetic Teaching Nurses of Southern California, Monrovia, California; September 1983
20. *Diabetic Retinopathy*
Nursing Seminar, Western Medical Center, Santa Ana, California; May 1984
21. *Diabetes: Combating the Complications*
Diabetes Teaching Nurses of Southern California, San Bernardino, California; October 1984
22. *Retinal Disorders*
Braille Institute Anaheim, Instructors Conference, Anaheim, California; October 1985
23. *Mizuo-Nakamura Phenomenon in Late Onset Dominant Cone Degeneration*
Macula Society--Eighth Annual Scientific Meeting, Marathon, Florida; February 1985
Presentation by John Heckenlively, M.D.
24. *Macular Degeneration*
Invited Speaker. Medical Society of Leisure World; April 15, 1990
25. *Diabetic Retinopathy-The Message and Challenge of Diabetes 2000*
Invited Speaker. Hawaiian Eye Foundation, Maui, Hawaii; January 25, 1991
26. *Diabetic Retinopathy*
Operating Room Nurses Presentation. Hoag Memorial Hospital Presbyterian, Newport Beach, California; June 26, 1991
27. *Laser Indirect Ophthalmoscopy*
American College of Surgeons, Palm Springs, California; January 1992
28. *Diabetic Retinopathy*
Invited Speaker. Medical Society of Leisure World; April 15, 1992
29. *Intraocular Pressure Swings During Closed Pars Plana Vitrectomy Surgery*
American College of Surgeons, Annual Meeting So. Calif. Chapter, Santa Barbara, California; January 24, 1993
30. *Intraocular Pressure Swings During Closed Pars Plana Vitrectomy Surgery*
Advanced Vitreoretinal Symposium in Honor of Thomas Aaberg M.D., Medical College of Wisconsin, Kohler, Wisconsin; April 17, 1993
31. *Infrared Laser Indirect for Retinopathy of Prematurity*
Invited Speaker. American College of Surgeons, Annual Meeting So. Calif. Chapter, Hyatt Hotel, Newport Beach; January 22, 1994
32. *Ultrasonographic and Physiologic Opaque Media Testing*
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; March 16, 1994

33. *Putting the Patient First and Surviving Bureaucratic Nonsense*
Invited Speaker Commencement Address to Graduating Residents. University of California, Irvine, Department of Ophthalmology; June 15, 1994
34. *Opaque Media Testing & Laser Indirect Treatment of Retinopathy*
Invited Speaker. Orange County Optometric Society, Ocular Pathology Symposium '94 Western Medical Center-Bash Auditorium, Santa Ana, California; August 28, 1994
35. *Practical Considerations and Advances In Vitreo-Retinal Diseases*
Invited Speaker. Ocular Pathology Symposium '96, Orange County Optometric Society, Irvine Medical Center, California; August 18, 1996
36. *Advanced Phaco Techniques for Best Demonstrated Outcomes: Retinal Surgeon's View of Cataract Complications*
Alcon Ophthalmic Symposium, Newport Beach, California; Sept. 20-22, 1996
37. *Advanced Phaco Techniques for Best Demonstrated Outcomes: Posterior Segment Complications - What the Anterior Surgeon Should Not Do*
Featured Speaker, Alcon Ophthalmic Symposium, Newport Beach, California; September 21, 1996
38. *Opaque Media Testing & Retinal Dystrophies*
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 26, 1997
39. *Opaque Media Testing*
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 11, 1998
40. *Understanding Medical Savings Accounts-Putting the Patient First*
American College of Surgeons, Rancho Mirage, California; January 31, 1998
41. *Opaque Media Testing*
Invited Lecture to UCI Residents. University of California, Irvine, Department of Ophthalmology; February 11, 1998
42. *Intraocular Pressure During Posterior Vitrectomy Surgery*
Western Retina Study Club, Tenth Annual Meeting, San Francisco, California; March 16-17, 1998
43. Western Retina Study Club Eleventh Annual Meeting Newport Beach, California; March 12-13, 1999
44. *Macular Retinal Disease Identification and Progression*
Ophthalmic Photographers' Society Mid-Year Meeting, Jules Stein Eye Institute, University of California, Los Angeles; June 25, 1999
45. *Plaquenil Maculopathy - A Review of Diagnosis and Management*
American College of Surgeons Annual Scientific Meeting, Huntington Beach, California; January 23, 2000
46. *Retina Related Medical Malpractice*
Invited Speaker. American College of Surgeons Annual Scientific Meeting, Santa Barbara, California; January 21, 2001
47. *Angioid Streaks: Macular Hemorrhages from Indirect Trauma in a Patient with PXE without Pre-Existing Macular Breaks*
Macula Society 27th Annual Meeting, Las Vegas, Nevada; February 25-28, 2004

48. *The Great Debates: Controversies in Retinal Disease 2005*
Invited Participant. Medical Education Seminar, University of California, Irvine, Beckman Laser Center, Irvine, California; March 26, 2005
49. *Update on Wet Macular Degeneration*
Invited Participant. International Academy of Low Vision Specialists, San Diego, California; November 5, 2011
50. *Referral of Low-Vision Patients by Retina Specialist*
Invited Participant. International Academy of Low Vision Specialists, San Diego, California; November 5, 2011
51. *Retina Psychophysiological Diagnostic Testing*
Retina Care Symposium, Costa Mesa, California; December 5, 2013
52. *Retina-related Malpractice*
Retina Care Symposium, Costa Mesa, California; December 5, 2013

PROFESSIONAL EXPERIENCE

Establishment and directorship of retinal function testing laboratory, Loyola University Hospital, Chicago, Illinois in 1974; Consultation service through 1977.

Monthly Lecturer, Physiology of the Retina Seminar, Loyola University Medical Center, Chicago, Illinois, 1975-1977

Participation in F.O.C.U.S. program, Eye Clinic, Port-du-Paix, Haiti, March 1976

Director and lecturer, monthly fluorescein angiography seminar, Eye Institute, The Medical College of Wisconsin, Milwaukee, Wisconsin, 1977-1978

Establishment of ultrasound testing, Eye Clinic, Long Beach Veterans Administration Hospital, Long Beach, California, 1978

Establishment of Vitrectomy Surgery Unit, Long Beach Veterans Administration, Hospital, Long Beach, California, 1978

Establishment of Ocular Ultrasonography Unit, University of California, Irvine Medical Center, Orange, California, 1978

Director of Retinal Physiology, Western Medical Center, Santa Ana, California, 1979 – 1998

Ultrasonography and Retina Clinic, University of California, Irvine, Medical Center, Orange, California, 1978-1980

Ultrasonography and Retina Clinic, Long Beach Veterans Administration Hospital, Long Beach, California; 1978 - 1996

Medical Director, Ophthalmology Laboratory, Hoag Memorial Hospital Presbyterian, Newport Beach, California, 1988 - 1993

Medical Director, Ophthalmology Laboratory, Western Medical Center, Santa Ana, California, October 1990 - 1998

Participant, Vitreoretinal Advisory Council, Alcon Laboratories, Inc.-Irvine, California, Laguna Hills, California; April 11-14, 1991

Alcon Retina Advisory Council, Annual Meeting, Monterey, California, March 25 - 27, 1994

Alcon Laboratories, Inc., Executive Conference and Tour, ACCURUS™ Model Research, Irvine Technology Center, Irvine, California; July 30, 1998

+

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Texas, Vitreoretinal Surgery Technology & ACCURUS™ Model Research, Napa Valley, California; August 6-8, 1998

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Palm Beach, Florida; May 10 – 12, 2002

Retinal Advisory Council Symposium, Alcon Laboratories, Inc., Nantucket, Massachusetts; June 20 – 22, 2003

COURSES DIRECTED

Basic Vitrectomy Course/Lab and Lecture Sessions, Western Medical Center, Santa Ana, California; October 26 & 27, 1979

Anterior Segment Ocutome/Fragmatome, System Symposium and Workshop, Hoag Memorial Hospital, Presbyterian, Newport Beach, California; May 6 & 7, 1983

Practical Methods in Diabetes Management, 1st Annual Meeting, Westin South Coast Plaza, Costa Mesa, California; November, 1990

Practical Methods in Diabetes Management, 2nd Annual Meeting, Newport Beach, CA; November 1 & 2, 1991

PUBLIC PRESENTATIONS

01. Research Approaches and Advances in Retinitis Pigmentosa and Related Diseases
National Retinitis Pigmentosa Foundation, Chicago, Illinois; May 1977
02. *Retinitis Pigmentosa and Related Diseases* National Retinitis Pigmentosa Foundation
Western Medical Center, Santa Ana, California; February 1980
03. *Diabetes and the Eye*
American Diabetes Association, Orange County Chapter, Anaheim Convention Center, Anaheim, California; May 1982
04. *Diabetic Retinopathy*
Diabetes Outreach Program, Eisenhower Medical Center, Palm Springs, California; April 1984
05. *History of Vitrectomy Surgery*
Featured Speaker. Alcon National Engineering and Sales Meeting, Newport Beach; February 1990
06. *Beyond the Basics: Diabetes and The Eye*
Seminar Director and Lecturer. American Diabetes Association-Orange County Chapter, Western Medical Center, Santa Ana, California; October 27, 1990
07. *Eye Complications in Diabetes*
Orange Aid, Orange Association of Diabetes Educators, Fullerton, California; April 17, 1991

08. *Beyond the Basics - Diabetes and the Eye*
American Diabetes Association, Saddleback Memorial Hospital, Laguna Hills, California;
March 21, 1992
09. *New Technologies of Laser Indirect Ophthalmoscopy Systems*
Invited Speaker. Nidek National Sales & Engineering Meeting, Carmel Highlands Resort, San Diego,
California; April 9, 1992
10. Invited Speaker with Patrick Farrell M.D., Charles W. Skoien, Jr., Consultant, Community Residential
Care Association of California; November 1992
11. Lecture. Sun Valley High School (Bruce Peterson, Chief Science Teacher); February 2, 1993
12. *Complications In the Eye As A Result of Diabetes*
Invited Speaker. American Diabetes Association-Orange County Chapter, Pump Group, Western Medical
Center, Santa Ana, California; May 11, 1993
13. *Fibromyalgia and the Eyes*
Invited Speaker. One on One Fibromyalgia Support Group (Karen Brooks, Executive Director), Hoag
Conference Center, Newport Beach, California; October 25, 1993
14. *Ophthalmology and Diabetes*
Invited Speaker. American Diabetes Association-Los Angeles Chapter, Pump Group, 5th Annual
Diabetes Faire, Long Beach Memorial Medical Center, Long Beach, California; November 6, 1993
15. *Diabetic Retinopathy: The Importance of Blood Sugar Control*
St. Joseph Hospital-ADA Support Group, Orange Senior Center, Orange, California; January 3, 1995
16. *Importance of Diabetic Control in Diabetic Retinopathy*
Project Health, Saddleback Memorial Hospital Medical Center, Laguna Hills, California;
January 24, 1995
17. *Diabetes Control: Lookin' Good*
Patient Education Seminar, American Diabetes Association, Irvine Marriott, Irvine, California;
June 25, 1995
18. *Fibromyalgia and the Eyes*
Invited Speaker. One on One Fibromyalgia Support Group, Hoag Hospital Conference Center, Newport
Beach, California; February 26, 1996
19. *Diabetes and Eye Disease*
Invited Speaker. Costa Mesa Senior Center, Costa Mesa, California; March 8, 1996
20. *Diabetic Retinopathy*
Invited Speaker. American Diabetes Association-Orange County Chapter, Western Medical Center, Santa
Ana, California; October 1, 1996
21. *Macular Degeneration*
Guest Speaker. Costa Mesa-Orange Coast Lions Club, Costa Mesa, California; November 21, 1996
22. *Medical Savings Accounts - Why Consumers are Demanding This Choice*
Spring Symposium. St. Joseph Hospital, Invited Speaker, April 26, 1997
23. *Medical Savings Accounts*
Invited Speaker. Columbia West Anaheim Medical Center, Anaheim, California; December 5, 1997

24. *The Retina and Uveitis in Fibromyalgia and Related Disorders*
Invited Speaker. American Fibromyalgia Foundation, Newport Beach Marriott, Newport Beach, California; February 28, 1998
25. *Visual Disability: Technical Explanation of Current Definitions in C.F.R. section 20*
Invited Speaker. Orange County Bar Association, Social Security Disability Attorneys, Orange, California; September 18, 1998
26. *HMO's/Managed Care: A Medical/Legal Slight of Hand*
Speaker and Panelist. Orange County Trial Lawyers Association & Forensic Expert Witness Association Joint Symposium, Antonello's Ristorante, Santa Ana, California; February 18, 1999
27. *Diabetic Retinopathy*
Invited Speaker. Orange County Insulin Pump Group, Western Medical Center, Santa Ana, California; April 6, 1999
28. *How Diabetes Affects Vision?*
Invited Speaker. Hoag Memorial Hospital Presbyterian, Diabetic Support Group ("Naturally Sweet"), Newport Beach, California; May 10, 2000
29. *The Retina: Diseases & Current Research for a Cure*
City of Irvine, Senior Outreach Program, Lakeview Senior Center, Irvine, California; September 28, 2000
30. *Macular Degeneration: New Treatments*
Invited Speaker. L.A. Royal Vista Country Club, Rotary Club Meeting, Walnut, California; October 3, 2000
31. *Billing, Collection, Scheduling, & Time Management*
Speaker and Panelist. Forensic Expert Witness Association, Irvine, California; October 30, 2000
32. Commencement Address
Oakridge Private School (Directors: Mr. & Mrs. Fred Burry), Irvine, California; June 8, 2001
33. *Diabetic Retinopathy*
Invited Speaker. Orange County Insulin Pump Group, Western Medical Center, Santa Ana, California; September 3, 2002
34. *Diabetes and Eye Disease*
Invited Speaker. Costa Mesa Senior Center, Costa Mesa, California; October 8, 2004
35. *Diabetic Retinopathy*
St Joseph Hospital Diabetes Support Group/Diabetics United of Orange County, Orange, California; March 3, 2009
36. *Ophthalmology/Retina Career*
Career Day Presentation, MacArthur Intermediate School, Santa Ana, California; March 25, 2009
37. *Retinal Physiology*
Orange County Diabetes Resources Organization, California; December 3, 2013

BUSINESS, MANAGED CARE COURSES & EXPERIENCE

01. *Empowering Your Office Manager/Successful Challenging of Medicare Denials*
Ophthalmology Department-University of California, Irvine, Irvine, California; December 4, 1993
02. *Planning, Contracting & Negotiating with Managed Care*
Specialty Capitation & Risk Sharing Seminar, Institute for International Research, Coral Gables, Florida;
December 6 - 8, 1995
03. *Planning, Contracting & Negotiating with Managed Care*
Irwin Professional Seminar, Business Network; March 28, 1996
04. Irwin Professional Seminar
Business Network, University of California, Los Angeles, Jules Stein Eye Institute, Los Angeles,
California; March 28, 1996
05. Irwin Professional Seminar
Business Network, University of California, Los Angeles, Jules Stein Eye Institute, Los Angeles,
California; April 12 & 13, 1996

CONSULTANT/CLINICAL TRIALS

01. Alcon Retinal Advisory Council, Irvine, California, 1990 - 2010
02. Wyeth-Ayerst Pharmaceutical, 1990 - 1993
Principal Investigator. *The safety and efficacy of Tolrestat in the treatment of diabetic retinopathy*
03. Mini Med, Retinal Consultant, National and International Trials, 1990 - 2001
04. Chiron Ophthalmics, Retinal Consultant, 1991 - 1992
05. Innerspace, Intraocular Pressure Transducer Project, Irvine, California, 1991 - 1994
06. Allergan Medical Optics, May 1995 - October 1995
Intraocular Lens Research Project, Rabbit Model of Array Multifocal Intraocular Lens
Director of Research: Nicholas Tarantino, O.D, Arlene Gwon M.D.
Irvine, California
07. ACCURUS™, System Investigator, Alcon Surgical, Inc., Irvine, California; 1996 - 2000
08. California Advantage, Inc., Specialty Advisor, San Francisco, California; 1997-1998
09. Allergan Medical Optics, Irvine, California; June 4th, 1998
Implanted Vitreous Device, new product research
Project Discussion with medical researchers & engineers
Director of Research: Nicholas Tarantino, O.D, Arlene Gwon M.D., Valdemar Portney, Ph.D
10. CIBA/QLT PhotoTherapeutics, Protocol #BPD-OCR-005 (VAM); 1999-1999
Sub-Investigator. *An open-label multicenter safety study of the treatment of predominantly classic subfoveal CNV secondary AMD using PDT with verteporfin for injection*

11. Eyetech Pharmaceuticals, Protocol #EOP 1004, Phase II/III; 2001-2005
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD*
12. Novartis Ophthalmics, Protocol #CBPD952A2201 (ADD-V), Phase II; 2002-2002
Sub-Investigator. *ADjunctive Diclofenac therapy and Visudyne PDT (ADD-V): A three-month randomized, placebo-controlled, double-masked, multicenter study of the effect of adjunctive diclofenac therapy and Visudyne PDT in patients with predominantly classic subfoveal CNV secondary to AMD*
13. Alcon Research, Ltd., Protocol C-01-99, Phase III; 2002-2005
Principal Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD*
14. OxiGENE, Inc., Protocol MMD-213, Phase III; 2004-2006
Sub-Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia*
15. Diabetic Retinopathy Clinical Research Network/National Eye Institute, Protocol B; 2004-2009
Sub-Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME*
16. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III; 2004-2009
Sub-Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtasclear administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD*
17. National Eye Institute, SCORE; 2004-2009
Sub-Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO*
18. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV Collaborative Study; 2005-2006
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction.*
19. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III; 2005-2007
Principal Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 months in patients with exudative AMD*
20. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV; 2005-2007
Sub-Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD*
21. Novartis, Protocol CBPD952E2202 (Veritas), Phase IIIB; 2005-2007
Sub-Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal CNV secondary to AMD*

22. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV; 2006-2008
Sub-Investigator. *An open label, multicenter trial of maintenance intravitreal injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement*
23. Novartis, Protocol #CBPD952A2308 (Denali), Phase IIIB; 2006-2010
Sub-Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of vertporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis) monotherapy in patients with subfoveal CNV Secondary to AMD*
24. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III; 2006-2011
Sub-Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®)*
25. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III; 2006-2011
Sub-Investigator. *Clinical Evaluation of Anti-angiogenesis in the Retina - Intravitreal Trial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD*
26. Opko, Protocol ACU-301 (COBALT), Phase III; 2007-2009
Sub-Investigator. *Combining Bevasirinib and Lucentis Therapy (COBALT): A randomized, double-masked, parallel-assignment study of intravitreal bevasirinib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD*
27. Allergan, Protocol 206207-012, Phase III; 2007-2010
Sub-Investigator. *A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posterior-segment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME*
28. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III; 2007-2010
Sub-Investigator. *A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR*
29. Merck & Co., Protocol 007-01, Collaborative Study; 2008-2009
Sub-Investigator. *A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB*
30. Allergan, Protocol 206207-019-00, Phase II; 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD*
31. Ophthotec Corp., Protocol OPH3000, Phase 1; 2008-2010
Sub-Investigator. *An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreal injections of volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD*

32. Regeneron, Protocol VGFT-OD-0706 (Da Vinci) , Phase III; 2008-2011
Sub-Investigator. *A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME*
33. NEI/Tufts Medical Center, The Family Study of Macular Degeneration; 2009-2010
The goal is to evaluate genetic and non-genetic risk factors for AMD
34. Allergan, Protocol 206207-018-00, Phase II; 2009-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME*
35. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study; 2009-2011
Sub-Investigator. *A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy*
36. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study; 2010-2011
Sub-Investigator. *A, randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain*
37. GlaxoSmithKline, Protocol MD 7110852, Phase IIB; 2009-2012
Sub-Investigator. *A Phase dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD*
38. Genentech, Protocol FVF4579g, Phase III; 2009-2012
Sub-Investigator. *A, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD*
39. Lux Biosciences, Inc., Protocol LX211-11, Phase III; 2011-2013
Sub-Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis*
40. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA; 2011-Present
Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonecipzumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to age-relat*
41. Alimera, Protocol C-01-11-008, Extension Study; 2011-2013
Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME*
42. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013
Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*

43. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-2013
Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
44. Xoma, Protocol X052130/CL3-78989-005, Phase III, 2012-Present
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
45. Pfizer, Protocol B1181003-1050, Phase II, 2012-2013
Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
46. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-Present
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*
47. Regeneron Protocol VGFTe-AMD-1124 ((RE-VIEW), Phase IV, 2012-Present
Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
48. Merck Protocol MK8931—017 (SCH 900931, P07738), Phase 2/3, Collaborative Study, 2012-Present
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*
49. Ophthotech OPH1003, Phase III, 2013-Present
Sub-Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*

BIBLIOGRAPHY

01. **Maggiano JM**, Chen P, Marchese A, Friedman A. The electro-oculogram response to near UV light. *ARVO*;1975.
02. **Maggiano JM**, Kerman R, Mullenix C. Exacerbation of Behcet's syndrome by ingestion of English walnuts. *ARVO*;1976.
03. Fishman G, Fishman M, **Maggiano JM**. Macular lesions associated with retinitis pigmentosa. *Arch Ophthalmol* 1977 May;95(5):798-803.
04. Fishman GA, **Maggiano JM**, Fishman M. Foveal lesions seen in retinitis pigmentosa. *Arch Ophthalmol* 1977 November;Vol. 95, No. 11.
05. Merin S, **Maggiano JM**, Fishman GA. Retinal sensitivity under photopic conditions in patients with retinitis pigmentosa, and carriers of the X-linked recessive form. *Metab Ophthalmol* 1978;2:225-229.
06. Sieving PA, Fishman GA, **Maggiano JM**. Corneal wick electrode for recording early receptor potentials and bright flash electro-retinograms. *Arch Ophthalmol* 1978 May;96:899-900.
07. **Maggiano JM**, Fishman GA, Evans L, Goldbaum M. Calibration error in dark adaptometer. *Arch Ophthalmol* 1978 June;Vol. 96.
08. Neuman R, **Maggiano JM**, Frenkel M. Bilateral acute anterior ischemic optic neuropathy in diabetes. *Ann Ophthalmol* 1978 November;Vol.10, No.11.
09. **Maggiano JM**, Aaburg TM, Farina JF. Electrophysiologic abnormalities in juvenile x-linked retinoschisis. (Abstract) *ARVO* 1978.
10. **Maggiano JM**, Aaburg TM, Reeser F, Meredith TA, Kingham J. Factors influencing formation of serous choroidal detachment after retinal detachment surgery. (Abstract) *ARVO* 1979.
11. Aaberg T, **Maggiano JM**. Choroidal edema associated with retinal detachment repair; experimental and clinical correlation. *Modern Problems in Ophthalmology* 1979;20:6-14.
12. Gagrat D, **Maggiano JM**, Belmaker RH. Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram, and color vision. *Psychiatry Res* 1979 Jul;1(1):109.
13. McKeown C, Swartz M, Blom J, **Maggiano JM**. Tamoxifen retinopathy. *Brit J Ophthalmol* 1981;65:177-179.
14. Packer A, **Maggiano JM**, Aaberg T, Meredith T, Reeser F. Serous choroidal detachment after retinal detachment surgery. *Arch. Ophthalmol* 1983 August;Vol. 101, No. 8.
15. Schoessow D, **Maggiano JM** (Editor). To see or not to see? A patient's guide to diabetic retinopathy. Library of Congress, No. Txu 100-321, 1982; Library of Congress No. Tx1-095-946, 1983; Privately published: Feb.1983, Aug.1983, Nov. 1985, Feb.1996.
16. Arnold AC, Hepler RS, Yee RW, **Maggiano JM**, Eng LF, Foos RY. Solitary retinal astrocytoma. *Clin Path Rev* 1985 November-December;Vol. 30, No. 3, p. 173-181.
17. Ober RR, Wilkinson CP, Fiore JV Jr, **Maggiano JM**. Rhegmatogenous retinal detachment after neodymium-YAG laser capsulotomy in aphakic and pseudophakic eyes. *Am J Ophthalmol* 1986 January;101:81-89.

18. Belmaker RH, **Maggiano JM**. Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram and color vision. *Psychiatry Research* 1979 Jul;1(1):109.
19. Marchese AL, **Maggiano JM**, Friedman AH. Comparison of the human electro-oculographic response to green and near-ultraviolet stimuli. *Documenta Ophthalmologica* 1992;79:117-124.
20. Glasgow B, **Maggiano JM**. Cuterebra ophthalmomyiasis. *Am J Ophthalmol* 1995 April;Vol.119, No. 4.
21. You TT, Youn DW, Chen S, Alexandrescu B, **Maggiano JM**, Casiano ME,. Intraocular penetration by acupuncture needle.(submitted for publication 2012, *Retina*)